CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
exenatide 5 mcg +2 moredrug
Likely dose
exenatide 5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01154933
NCT01154933Phase 2Completed
CompareCT.gov

The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin

University at Buffalo·interventional·Posted Jul 1, 2010·Updated Oct 6, 2022

In Brief

A Phase 2 clinical trial evaluating exenatide 5 mcg, exenatide 10 mcg, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsAmylin Pharmaceuticals, LLC.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 1, 2010
Enrollment StartApr 1, 2008
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 16.0 years ago

Interventions

exenatide 5 mcgdrug

exenatide 5 mcg

exenatide 10 mcgdrug

exenatide 10 mcg

placebodrug

saline sq